A Phase 2 Multicenter Study of TL-895 in Subjects With Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis, Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis, or Indolent Systemic Mastocytosis

Description

This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis (Cohorts 1-3) or Indolent Systemic Mastocytosis (Cohort 5). Participants must be diagnosed with Myelofibrosis and be relapsed/refractory (e.g., having failed prior therapy), intolerant, or ineligible to receive JAKi treatment, or be diagnosed with Indolent Systemic Mastocytosis.

Trial Eligibility

Cohorts 1-3 Key Inclusion Criteria: * Adults ≥18 years of age * Confirmed diagnosis of PMF, post-PV MF, or post-ET MF, as assessed by treating physician according to the World Health Organization (WHO) criteria * Eastern Cooperative Oncology Group (ECOG) performance status of ≤2 * Adequate hematologic, hepatic, and renal functions * MF symptoms as defined by having at least 2 symptoms with an average baseline (Day -7 to Day -1) score of at least 1 for each of the 2 symptoms per MFSAF v4.0 * Cohort 3 only: Ineligibility for JAKi treatment with a platelet count of ≥ 25 and \< 50 x 10\^9/L Key Exclusion Criteria: * Prior treatment with any BTK or BMX inhibitors * Prior treatment with JAKi within 28 days prior to study treatment * Prior splenectomy or splenic irradiation within 24 weeks prior to first dose of study treatment Cohort 5 Key Inclusion Criteria: * Adults ≥18 years of age * Confirmed diagnosis of ISM as defined by WHO diagnostic criteria based on review of bone marrow biopsy pathology report results * Subject must have moderate-to-severe symptoms Key Exclusion Criteria: * Prior treatment with any BTK or BMX inhibitors * Prior treatment with Avapritinib, bezuclastinib, or BLU-263/elenestinib * Diagnosis with another myeloproliferative disorder

Study Info

Interventions

Locations Recruiting

Interested in joining this trial?

Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.